Elizabeth Mitchell, MD
Ophthalmology · Madison, MSNPI 1962430074
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 221 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 20.7% — the pattern of someone who eats at a lot of different presentations.
Across 221 payments — averaging $24.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Oyster Point Pharma, Inc.$1K
- Bausch & Lomb Americas Inc.$559
- Johnson & Johnson Surgical Vision, Inc.$469
- Bausch & Lomb, A Division Of Bausch Health US, LLC$427
- Glaukos Corporation$269
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,35199%
- Gifts$391%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 49 | $1,114 |
| Oyster Point Pharma, Inc. | 37 | $1,051 |
| Bausch & Lomb Americas Inc. | 25 | $559 |
| Johnson & Johnson Surgical Vision, Inc. | 8 | $469 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 19 | $427 |
| Glaukos Corporation | 8 | $269 |
| Ocular Therapeutix, Inc. | 10 | $202 |
| Novartis | 13 | $184 |
| Mallinckrodt Hospital Products Inc. | 6 | $134 |
| Dompe US, Inc. | 1 | $120 |
| Biotissue Holdings Inc. | 3 | $105 |
| Sun Pharmaceutical Industries Inc. | 6 | $101 |
| Tarsus Pharmaceuticals, Inc. | 4 | $91 |
| Rayner Intraocular Lenses Limited | 2 | $55 |
| Thea Pharma Inc. | 3 | $55 |
| Aerie Pharmaceuticals, Inc. | 3 | $54 |
| Sight Sciences, Inc. | 3 | $47 |
| Alcon | 3 | $47 |
| Carl Zeiss Meditec AG | 2 | $39 |
| Kala Pharmaceuticals, Inc. | 2 | $37 |
| Shire North American Group Inc | 3 | $36 |
| ANI Pharmaceuticals, Inc. | 2 | $34 |
| Harrow Eye, LLC | 1 | $32 |
| Amgen | 2 | $29 |
| Rxsight Inc | 2 | $28 |
| Eyevance Pharmaceuticals LLC | 2 | $27 |
| Beaver-visitec International, Inc. | 1 | $21 |
| Eyepoint US, Inc. | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- TYRVAYA$264
- XEN GLAUCOMA TREATMENT SYSTEM$139
- BOTOX$137
- MIEBO$123
- Oxervate$120
- iStent inject W$111
- KXL System$111
- Photrexa$111
- CATALYS SYSTEM$106
- Catalys Laser System$102
How this compares
$5,390 in reported general payments places this provider in the 80th percentile of 150 ophthalmology providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 63 | $56,216 |
| XiidraLifitegrast | 31 | $27,045 |
| LumiganBimatoprost | 63 | $25,840 |
| CombiganBrimonidine Tartrate/Timolol | 51 | $15,538 |
| Prednisolone Acetate | 190 | $7,598 |
| AlrexLoteprednol Etabonate | 11 | $6,944 |
| Cyclosporine | 13 | $5,091 |
| VyzultaLatanoprostene Bunod | 12 | $3,727 |
| Latanoprost | 257 | $3,118 |
| Timolol Maleate | 128 | $2,411 |
| Flurbiprofen Sodium | 77 | $1,947 |
| Doxycycline Hyclate | 93 | $1,613 |
| Loteprednol Etabonate | 16 | $1,472 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 63 | $1,462 |
| Dexamethasone Sodium Phosphate | 32 | $1,427 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan | $1,114 | $97,593177 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta | $559 | $30,77243 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCAlrex, Loteprednol Etabonate | $427 | $8,41627 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 150 ophthalmology providers in Mississippi.
Other ophthalmology in Madison
- William AshfordMadison$13K
- Philip SmithMadison$5K
- Robert BrowningMadison$4K
- Kevin KosekMadison$4K
- Alexander WhittingtonMadison$3K
- Kiper NelsonHattiesburg$234K
- John ParkerTupelo$72K
- Joseph ChildsTupelo$42K
- Heather HancockJackson$39K
- Leslie AdenFlowood$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.